T1 Mapping of Diffuse Myocardial Fibrosis in Congenital Heart Disease

Launched by THE HOSPITAL FOR SICK CHILDREN · Jan 26, 2015

Keywords

ClinConnect Summary

A better understanding of the mechanisms by which the heart muscle fails in pediatric heart disease may result in novel therapies directed at preventing rather than treating ventricular failure. The most likely mediator candidate for cardiac demise in congenital heart disease as well as the cardiomyopathies is diffuse myocardial fibrosis and non-favorable chronic biventricular remodeling. As such, fibrosis may be a marker, if not a mediator, preceding the onset of actual echocardiographic and clinical deterioration, opening opportunities for more timely and targeted treatment. Chronic stres...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: Patients with cardiomyopathies (clinically established diagnosis of dilated or hypertrophic cardiomyopathy) / Patients with congenital heart disease (Diagnosis of Transposition of the great arteries after arterial switch operation, repaired Tetralogy of Fallot, patients after single ventricle palliation at the Fontan stage) scheduled for an MR investigation including gadolinium (MRI contrast medium)
• • Patients / guardians capable of giving informed consent
• • Informed written consent / assent by the parents / legal guardians and patients where applicable
• • Ability to undergo a MRI examination without anaesthesia. Children \> 6 years are typically able to cooperate sufficiently.
• • Control Patients: Patients undergoing a non-cardiac MR investigation (musculoskeletal / abdomen / brain) including gadolinium without a history of cardiac disease
• • Exclusion Criteria:- Consent / assent refusal by guardian / patient
• • General contraindications for a MRI examination such as non-MRI compatible metallic implants, claustrophobia.
• • No contrast required for the clinical portion of the MRI
• • Patients who require anaesthesia for MRI (typically \< 6 years of age)
• • Known renal failure or previous allergic reaction to gadolinium containing contrast agent
• • Control subjects: history of cardiac problems, e.g. rhythm disorders, former myocarditis, active myositis or other inflammatory conditions except suspected or confirmed inflammatory bowel disease such as Crohn's disease or ulcerative colitis
• • Known pregnancy or breast feeding